How Do GLP-1 Medications Help Arthritis?

Introduction

For decades, the only medications for knee osteoarthritis worked on pain perception, not on the disease itself. NSAIDs blunt inflammation. Acetaminophen dulls signaling. Steroid injections buy weeks. None of them address the biggest driver: excess body weight pressing through cartilage that can’t repair itself. GLP-1 medications change that calculus, and the STEP 9 trial gave us the first phase 3 evidence.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey, and you can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Why GLP-1 Drugs Even Got Studied for Arthritis

The logic was simple. Obesity is the largest modifiable risk factor for knee and hip OA. Each pound of body weight transmits roughly 4 pounds of force through the knee during walking (Messier 2005). And weight loss via diet and exercise has been shown repeatedly to reduce pain. The IDEA trial (Messier 2013, JAMA) demonstrated that 10% weight loss plus exercise produced about 51% reduction in WOMAC pain in people with knee OA.

Quick Answer: STEP 9 (Bliddal 2024, NEJM) showed semaglutide 2.4 mg cut WOMAC pain 41.7 points versus 27.5 placebo over 68 weeks.

The problem with diet and exercise is that most people regain the weight. The longest-running diet trials show 50 to 80% regain by year 5. GLP-1 medications produce comparable or greater weight loss and, in trial settings, hold it for as long as treatment continues. So Novo Nordisk and the academic community ran STEP 9 to test whether the weight loss translates into OA benefit.

What STEP 9 Showed

STEP 9 (Bliddal et al., 2024, NEJM) randomized 407 adults with BMI over 30 and clinically and radiographically confirmed knee OA (Kellgren-Lawrence 2 or 3) to weekly semaglutide 2.4 mg or matching placebo, plus a lifestyle intervention, for 68 weeks. The co-primary endpoints were change in body weight and change in WOMAC pain score.

Body weight fell 13.7% in the semaglutide group versus 3.2% in placebo. WOMAC pain (a 0 to 100 scale where higher means more pain) dropped 41.7 points on semaglutide and 27.5 on placebo, a 14.2 point difference. The minimal clinically important difference for WOMAC pain in OA is generally cited at 7 to 10 points, so the semaglutide effect is meaningfully larger than placebo and exceeds typical effect sizes for oral NSAIDs.

WOMAC physical function improved by 41.5 points on semaglutide versus 26.7 on placebo. SF-36 physical component scores rose 12.0 points versus 6.5. Adverse events were the typical GLP-1 GI profile: nausea, diarrhea, constipation. Discontinuation rates from adverse events were 6.7% on semaglutide versus 3.0% on placebo.

How This Compares to NSAIDs

A 2017 BMJ network meta-analysis of 76 NSAID trials in OA found average pain reductions of 8 to 12 points on a 0 to 100 scale versus placebo over 8 to 12 weeks. Semaglutide’s 14.2 point effect over 68 weeks is at least as large, and unlike NSAIDs it doesn’t carry GI bleeding, cardiovascular, or renal risk profiles.

That doesn’t mean GLP-1 drugs replace NSAIDs. It means for someone with obesity and OA, semaglutide can produce NSAID-equivalent or better pain relief while addressing the underlying driver of disease.

The Mechanism: Weight, Inflammation, or Both?

Most of the benefit is mechanical. Drop 13.7% of body weight and your knees see roughly 4 times that reduction in load per step. Over thousands of steps daily, that’s the dominant mechanism.

But there’s likely more. GLP-1 receptor agonists reduce systemic inflammation. CRP drops 30 to 40% in the obesity trials. IL-6 and TNF-alpha both fall. Cartilage and synovium have GLP-1 receptors, and rodent studies (Meurot 2022, Annals of the Rheumatic Diseases) showed direct chondroprotective effects independent of weight loss.

The human cartilage data isn’t there yet. We don’t know if semaglutide slows structural OA progression on MRI. STEP 9 wasn’t designed to answer that. But the symptom benefit is real and robust.

SELECT Secondary Analyses

The SELECT trial (Lincoff 2023, NEJM) was the cardiovascular outcomes trial of semaglutide 2.4 mg in 17,604 adults with obesity and pre-existing CVD. A 2025 secondary analysis examined incident knee and hip replacement. Over a mean 39.8 months, the semaglutide group had a 20% lower rate of joint replacement procedures (HR 0.80, 95% CI 0.69 to 0.93) compared with placebo.

That’s not a randomized OA endpoint, but it’s a hard procedural outcome in a 17,000-person trial. The signal is consistent with STEP 9.

What About Tirzepatide?

Tirzepatide (Mounjaro®, Zepbound®) is a dual GIP/GLP-1 agonist that produces larger weight loss than semaglutide in head-to-head and indirect comparisons. SURMOUNT-1 (Jastreboff 2022, NEJM) showed mean 20.9% weight loss at 72 weeks on tirzepatide 15 mg versus 3.1% placebo, compared to STEP 1’s 14.9% on semaglutide 2.4 mg.

There’s no published phase 3 RCT of tirzepatide specifically in OA yet. SURMOUNT-OA is in development. Given the larger weight loss, mechanistic logic suggests at least equivalent and likely greater pain benefit. For now, off-label use in obese patients with OA is reasonable but not yet evidence-based to the same degree as semaglutide.

Who Should Consider GLP-1 for OA?

The clearest candidates are adults with BMI over 30 (or 27 with weight-related comorbidities) plus symptomatic knee or hip OA who haven’t achieved adequate relief from exercise, weight loss attempts, topical NSAIDs, and oral NSAIDs. STEP 9’s population was BMI 30+ with KL grade 2 or 3 knee OA, so the strongest evidence is in that profile.

If you have OA but normal BMI, GLP-1 medications aren’t appropriate. The mechanism is weight loss, and the FDA approval requires elevated BMI. For lean OA patients, the standard cascade applies.

If you have severe end-stage OA (KL grade 4) and significant disability, weight loss helps but joint replacement may still be the right call. GLP-1 medications can be used before surgery to optimize outcomes. Bariatric surgery before TKR has been shown to reduce surgical complications in patients with BMI over 40, and GLP-1 prehabilitation may produce similar benefits.

Side Effects to Know About

The big ones are nausea, vomiting, diarrhea, constipation, and reduced appetite. Most are dose-dependent and improve over weeks. The titration schedule (0.25 mg to 2.4 mg over 16 weeks for semaglutide) is designed to limit GI symptoms.

Less common but serious: pancreatitis, gallbladder disease, gastroparesis. Contraindicated if personal or family history of medullary thyroid carcinoma or MEN2.

For OA patients specifically, watch for sarcopenia. Rapid weight loss can take muscle along with fat. The muscle around your arthritic joint is what protects it. Resistance training during GLP-1 therapy isn’t optional, it’s necessary. Aim for at least 2 strength sessions weekly and adequate protein (1.0 to 1.2 g per kg of target body weight).

Key Takeaway: The 14.2 point WOMAC pain difference exceeds the 7 to 10 point minimal clinically important difference for the scale.

How Long to Stay on Treatment?

The honest answer is indefinitely if you want the weight loss to hold. STEP 1 extension data showed two-thirds of weight returns within a year of stopping semaglutide. For OA, that means pain likely returns too. Most clinicians treat GLP-1 therapy as chronic disease management, the same way they treat antihypertensives or statins.

If cost or access becomes a barrier, transitioning slowly with intensified lifestyle support gives the best chance of maintaining gains. Some patients do well at lower maintenance doses (1.0 to 1.7 mg semaglutide weekly).

STEP 9 Subgroup Data Worth Knowing

The pre-specified subgroup analyses in STEP 9 help predict individual response. Pain reduction was consistent across age groups (under 60 vs 60+), sex, baseline BMI tertiles (30 to 35, 35 to 40, over 40), and Kellgren-Lawrence grade 2 vs grade 3 disease. The benefit was seen even in patients losing less than 5% of body weight, suggesting the inflammatory and metabolic components of the mechanism contribute alongside pure mechanical unloading.

What stayed less clear: whether structural progression on imaging slows. The trial wasn’t powered for MRI cartilage endpoints. SURMOUNT-OA, when it reads out, is expected to include some imaging data.

How GLP-1 Affects Pain Pathways Beyond Weight

Three mechanisms beyond weight reduction are biologically plausible. First, systemic inflammation drops. CRP fell about 36% in STEP 9, IL-6 dropped, and TNF-alpha trends downward in the larger STEP and SUSTAIN datasets. Lower systemic inflammation likely affects synovial inflammation in OA joints.

Second, GLP-1 receptors exist in the central nervous system at sites involved in pain modulation. Animal models (Gong 2014, Pain) show GLP-1 agonism reduces inflammatory pain independent of weight changes.

Third, gut microbiome shifts. GLP-1 medications change microbial composition in ways that may reduce systemic inflammation, although the human OA-specific data is preliminary.

These mechanisms add up to roughly half the WOMAC pain effect in mechanistic models, with weight loss accounting for the other half. That ratio matters for understanding what happens when patients lose less weight than expected.

Combining GLP-1 with Other OA Treatments

GLP-1 medications layer with topical NSAIDs, oral NSAIDs, PT, and injections. There’s no pharmacologic interaction with diclofenac gel, ibuprofen, naproxen, celecoxib, acetaminophen, duloxetine, or intra-articular corticosteroids.

The practical issue is GI tolerability. Nausea from GLP-1 titration can be amplified by oral NSAIDs. If you’re starting both around the same time, separate them by a few weeks if possible, take NSAIDs with food, and add a PPI if epigastric symptoms develop.

Many STEP 9 participants reduced NSAID use as the trial progressed. By week 68, NSAID consumption was about 40% lower in the semaglutide arm than placebo. That’s a real safety benefit, since long-term NSAID use carries cardiovascular, renal, and GI risks.

Cost Reality and Access

US list prices in 2024 ran around $1,300/month for Wegovy® and $1,000/month for Zepbound without insurance. Coverage under obesity indications has expanded but remains uneven. Medicare doesn’t cover GLP-1 for obesity alone (though it does for diabetes and recently approved cardiovascular indications). Private plans vary widely.

Workarounds patients use: prior authorization with documentation of BMI plus comorbidities, manufacturer savings cards (often $25 to $250/month for commercial insurance), and shifting between Wegovy and Zepbound based on coverage. Compounded semaglutide and tirzepatide became less available in 2025 after FDA restrictions tightened.

If cost is prohibitive, the highest-yield alternative for OA in obesity remains the IDEA-style intensive lifestyle intervention. Not as easy or as effective on average, but real.

Side-by-side: Semaglutide vs Typical OA Treatments

Treatment	Pain reduction (vs placebo)	Duration of benefit	Disease-modifying potential
Semaglutide 2.4 mg	~14 pts WOMAC over 68 wks	As long as on therapy	Likely (via weight + inflammation)
Oral NSAIDs	8 to 12 pts over 8 to 12 wks	While taking	None
Topical diclofenac	~40% reduction over 12 wks	While applying	None
Steroid injection	Variable, 4 to 8 wks	Short-term	Possibly negative (McAlindon 2017)
Hyaluronic acid	~2 pts on 100 mm VAS	Limited	None
10% weight loss + exercise	~30 to 50% reduction	Sustained while maintained	Yes

Myth vs. Fact: Setting the Record Straight

Misconceptions about treatment can delay good decisions. Here are three worth correcting before you make any choices about your care.

Myth: Osteoarthritis means your cartilage is shot and surgery is the only fix. Fact: Most patients improve significantly with weight loss and exercise. The IDEA trial showed weight loss + exercise produced better outcomes than either alone. Joint replacement is for end-stage cases that fail conservative therapy.

Myth: GLP-1 medications can’t help joint pain. Fact: The STEP 9 trial (2024) showed semaglutide reduced WOMAC pain scores by 41.7 points in obese patients with knee OA, comparable to the effect size of NSAIDs. The mechanism is weight loss plus anti-inflammatory effects.

Myth: Glucosamine and chondroitin will fix your knees. Fact: The GAIT trial showed glucosamine and chondroitin produced no statistically significant pain reduction beyond placebo in most patients. Save the money. Weight loss and exercise have far stronger evidence.

The Path Forward with TrimRx

Managing your metabolic health shouldn’t be a journey you take alone. The science behind GLP-1 medications offers a new level of hope for people facing arthritis and the related challenges that come with it. By addressing root hormonal and metabolic causes, these treatments provide a path toward more stable energy, better cardiovascular health, and improved quality of life.

At TrimRx, we’re committed to providing an empathetic and transparent experience. We understand the frustrations of traditional healthcare: the long waits, the unclear costs, and the lack of personalized care. Our platform is designed to put you back in control of your health. By combining clinical expertise with modern technology, we help you access the treatments you need while providing the 24/7 support you deserve.

Our program includes:

• Doctor consultations: professional guidance without the in-person waiting room
• Lab work coordination: baseline health markers monitored properly
• Ongoing support: 24/7 access to specialists for dosage changes and side effect management
• Reliable medication access: FDA-registered, inspected compounding pharmacies prepare Compounded Semaglutide or Compounded Tirzepatide when branded medications aren’t the right fit

Sustainable health is about more than a number on a scale or a single lab result. It’s about feeling empowered in your own body. Whether you’re starting to research your options or ready to take the next step with a free assessment, we’re here to guide you with science-backed, personalized care.

Bottom line: TrimRx provides a streamlined, medically supervised path to access the latest advancements in arthritis and weight management, all from the comfort of home.

FAQ

Will Insurance Cover GLP-1 for Arthritis?

Coverage is for the obesity or diabetes indication, not OA specifically. If your BMI is over 30 (or 27 with comorbidities), Wegovy or Zepbound may be covered for weight loss. Mounjaro and Ozempic® require type 2 diabetes for label coverage. Check your formulary.

How Fast Does Pain Improvement Happen?

In STEP 9, pain scores started diverging from placebo around week 12 to 16, paralleling early weight loss. By week 28, the gap was clear. Maximum benefit was around 52 to 68 weeks. Don’t expect overnight relief.

Should I Stop My NSAID If I Start a GLP-1?

Not necessarily. Many patients reduce NSAID use as weight comes off and pain drops, but you can use both. Coordinate with your clinician, especially regarding GI risk, since GLP-1 medications can cause nausea that NSAIDs may worsen.

Does the Pain Return If I Stop the Medication?

Likely, in proportion to weight regain. The mechanism is weight loss plus inflammation reduction, both of which reverse when treatment stops. Plan for chronic therapy unless you can hold the weight loss with intensive lifestyle work.

Is Tirzepatide Better Than Semaglutide for Joint Pain?

We don’t have a head-to-head trial in OA yet. Based on weight loss differences in obesity trials, tirzepatide likely produces equal or larger pain reduction. If your insurance covers either, both are reasonable.

Can I Do a GLP-1 Instead of Getting a Knee Replacement?

For some patients with moderate OA and obesity, yes, at least for years. STEP 9 showed substantial pain and function gains comparable to non-surgical interventions. For end-stage OA with bone-on-bone changes, joint replacement remains the definitive treatment.

How Does STEP 99 Compare to Bariatric Surgery for OA?

Bariatric surgery produces 25 to 35% sustained weight loss versus 13.7% with semaglutide in STEP 9. Observational studies (King 2018, JAMA Surgery) report substantial OA pain improvements after sleeve gastrectomy and Roux-en-Y. No head-to-head RCT yet. For BMI over 40 with severe OA, surgery remains a reasonable consideration. For BMI 30 to 40, GLP-1 is usually tried first.

What WOMAC Pain Reduction Is Considered Clinically Meaningful?

The minimal clinically important difference for WOMAC pain (0 to 100 scale) is 7 to 10 points. STEP 9’s 14.2-point semaglutide-vs-placebo difference clears that bar comfortably. Oral NSAIDs typically produce 8 to 12 point pain advantages over placebo in OA trials.

What About People with Normal BMI and OA?

GLP-1 medications aren’t appropriate. The mechanism is weight loss plus inflammation reduction, and regulatory approval requires elevated BMI. For lean OA patients, the standard cascade applies. Some research is exploring direct chondroprotective effects independent of weight, but trials in normal-weight OA patients aren’t underway.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.